133 related articles for article (PubMed ID: 38153044)
1. A Multifunctional Liposome for Synergistic Chemotherapy with Ferroptosis Activation of Triple-Negative Breast Cancer.
Chai J; Hu J; Wang T; Bao X; Luan J; Wang Y
Mol Pharm; 2024 Feb; 21(2):781-790. PubMed ID: 38153044
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cannabinoid receptor type 1 sensitizes triple-negative breast cancer cells to ferroptosis via regulating fatty acid metabolism.
Li P; Lin Q; Sun S; Yang N; Xia Y; Cao S; Zhang W; Li Q; Guo H; Zhu M; Wang Y; Zheng Z; Li S
Cell Death Dis; 2022 Sep; 13(9):808. PubMed ID: 36130940
[TBL] [Abstract][Full Text] [Related]
3. Metal-Polyphenol-Network Coated Prussian Blue Nanoparticles for Synergistic Ferroptosis and Apoptosis via Triggered GPX4 Inhibition and Concurrent In Situ Bleomycin Toxification.
Zhou L; Chen J; Li R; Wei L; Xiong H; Wang C; Chai K; Chen M; Zhu Z; Yao T; Lin Y; Dong C; Shi S
Small; 2021 Nov; 17(47):e2103919. PubMed ID: 34623753
[TBL] [Abstract][Full Text] [Related]
4. Glycyrrhetinic acid induces oxidative/nitrative stress and drives ferroptosis through activating NADPH oxidases and iNOS, and depriving glutathione in triple-negative breast cancer cells.
Wen Y; Chen H; Zhang L; Wu M; Zhang F; Yang D; Shen J; Chen J
Free Radic Biol Med; 2021 Sep; 173():41-51. PubMed ID: 34271106
[TBL] [Abstract][Full Text] [Related]
5. SRSF1 inhibits ferroptosis and reduces cisplatin chemosensitivity of triple-negative breast cancer cells through the circSEPT9/GCH1 axis.
Song X; Wang X; Chen X; Yu Z; Zhou Y
J Proteomics; 2024 Feb; 292():105055. PubMed ID: 38040194
[TBL] [Abstract][Full Text] [Related]
6. Disulfiram/Copper Induce Ferroptosis in Triple-Negative Breast Cancer Cell Line MDA-MB-231.
Chu M; An X; Fu C; Yu H; Zhang D; Li Q; Man X; Dai X; Li Z
Front Biosci (Landmark Ed); 2023 Aug; 28(8):186. PubMed ID: 37664913
[TBL] [Abstract][Full Text] [Related]
7. Multienzyme-like Reactivity Cooperatively Impairs Glutathione Peroxidase 4 and Ferroptosis Suppressor Protein 1 Pathways in Triple-Negative Breast Cancer for Sensitized Ferroptosis Therapy.
Li K; Lin C; Li M; Xu K; He Y; Mao Y; Lu L; Geng W; Li X; Luo Z; Cai K
ACS Nano; 2022 Feb; 16(2):2381-2398. PubMed ID: 35041395
[TBL] [Abstract][Full Text] [Related]
8. A MOF-Based Potent Ferroptosis Inducer for Enhanced Radiotherapy of Triple Negative Breast Cancer.
Zeng L; Ding S; Cao Y; Li C; Zhao B; Ma Z; Zhou J; Hu Y; Zhang X; Yang Y; Duan G; Bian XW; Tian G
ACS Nano; 2023 Jul; 17(14):13195-13210. PubMed ID: 37256771
[TBL] [Abstract][Full Text] [Related]
9. Glutathione depletion and dihydroorotate dehydrogenase inhibition actuated ferroptosis-augment to surmount triple-negative breast cancer.
Zhou TJ; Zhang MM; Liu DM; Huang LL; Yu HQ; Wang Y; Xing L; Jiang HL
Biomaterials; 2024 Mar; 305():122447. PubMed ID: 38154441
[TBL] [Abstract][Full Text] [Related]
10. Regulatory network of ferroptosis and autophagy by targeting oxidative stress defense using sulfasalazine in triple-negative breast cancer.
Takatani-Nakase T; Ikushima C; Sakitani M; Nakase I
Life Sci; 2024 Feb; 339():122411. PubMed ID: 38184272
[TBL] [Abstract][Full Text] [Related]
11. Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells.
Ding Y; Chen X; Liu C; Ge W; Wang Q; Hao X; Wang M; Chen Y; Zhang Q
J Hematol Oncol; 2021 Jan; 14(1):19. PubMed ID: 33472669
[TBL] [Abstract][Full Text] [Related]
12. A Fe(III)-porphyrin-oxaliplatin(IV) nanoplatform for enhanced ferroptosis and combined therapy.
Hu X; Li R; Wu W; Fang K; Zhu Z; Wang Y; Zhou L; Chen M; Dong C; Shi S
J Control Release; 2022 Aug; 348():660-671. PubMed ID: 35716884
[TBL] [Abstract][Full Text] [Related]
13. Ferroptosis induction via targeting metabolic alterations in triple-negative breast cancer.
Wang Y; Sun Y; Wang F; Wang H; Hu J
Biomed Pharmacother; 2023 Dec; 169():115866. PubMed ID: 37951026
[TBL] [Abstract][Full Text] [Related]
14. Targeted exosome-encapsulated erastin induced ferroptosis in triple negative breast cancer cells.
Yu M; Gai C; Li Z; Ding D; Zheng J; Zhang W; Lv S; Li W
Cancer Sci; 2019 Oct; 110(10):3173-3182. PubMed ID: 31464035
[TBL] [Abstract][Full Text] [Related]
15. Degradable iron-rich mesoporous dopamine as a dual-glutathione depletion nanoplatform for photothermal-enhanced ferroptosis and chemodynamic therapy.
Cheng H; He Y; Lu J; Yan Z; Song L; Mao Y; Di D; Gao Y; Zhao Q; Wang S
J Colloid Interface Sci; 2023 Jun; 639():249-262. PubMed ID: 36805750
[TBL] [Abstract][Full Text] [Related]
16. A Mitochondria-Targeted Ferroptosis Inducer Activated by Glutathione-Responsive Imaging and Depletion for Triple Negative Breast Cancer Theranostics.
Gan H; Huang X; Luo X; Li J; Mo B; Cheng L; Shu Q; Du Z; Tang H; Sun W; Wang L; Luo S; Yu S
Adv Healthc Mater; 2023 Sep; 12(22):e2300220. PubMed ID: 37204240
[TBL] [Abstract][Full Text] [Related]
17. Au-Fe
Wei R; Fu G; Li Z; Liu Y; Qi L; Liu K; Zhao Z; Xue M
J Colloid Interface Sci; 2024 Jun; 663():644-655. PubMed ID: 38430834
[TBL] [Abstract][Full Text] [Related]
18. A self-assembly nano-prodrug for triple-negative breast cancer combined treatment by ferroptosis therapy and chemotherapy.
Chen Y; Yao Z; Liu P; Hu Q; Huang Y; Ping L; Zhang F; Tang H; Wan T; Ping Y; Li B
Acta Biomater; 2023 Mar; 159():275-288. PubMed ID: 36709836
[TBL] [Abstract][Full Text] [Related]
19. Simvastatin induced ferroptosis for triple-negative breast cancer therapy.
Yao X; Xie R; Cao Y; Tang J; Men Y; Peng H; Yang W
J Nanobiotechnology; 2021 Oct; 19(1):311. PubMed ID: 34627266
[TBL] [Abstract][Full Text] [Related]
20. Iron ion and sulfasalazine-loaded polydopamine nanoparticles for Fenton reaction and glutathione peroxidase 4 inactivation for enhanced cancer ferrotherapy.
Zhu X; Chen Q; Xie L; Chen W; Jiang Y; Song E; Song Y
Acta Biomater; 2022 Jun; 145():210-221. PubMed ID: 35470077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
